Search results

Neoliberals often point to improvements in public health and nutrition as examples of globalisation's success, but this book argues that the corporate food and medicine industries are destroying environments and ruining living conditions across the world. Scientist Stan Cox expertly draws out the strong link between Western big business and environmental destruction. This is a shocking account of the huge damage that drug manufacturers and large food corporations are inflicting on the health...

In Lipids: Structure, Physical Properties and Functionality, Professor Kare Larsson, Peter Quinn, Kiyotaka Sato and Fredrik Tiberg have provided an up-to-date description of the diversity of lipid molecular arrangements in different physical states as a basis for the understanding of lipid functionality in biological and technical systems. Lipids are components of many complex systems, some of which are natural in origin, such as the cell membranes of living organisms, and others created by hum...

From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers. A past look at the biopharmaceutical industry provides answers to questions that most managers have. For example, what options do you have and what actions do you take when new firms enter your industry? I...

This book is the first of its kind in examining the role of biotechnology for reviving Indian agriculture and accelerating farmers’ incomes. It examines the empirical evidence in various agro-ecologies on already commercialised technologies, and also technologies on shelf like Bt brinjal, and herbicide tolerant maize and cotton. The political economy behind the public policies for biotechnologies, reasons for continuing controversies, and impacts of labelling policies and seed-pricing controls a...

Pharmaceutical Economics begins with an investigation of the structure of the industry and its three main components: the research firms which produce innovative products; the generic drug industry and its expanding role; and the biotech industry, which is regarded as the future for pharmaceuticals. Further sections discuss topics including demand and incentives, pricing and regulation. Professor Comanor and Professor Schweitzer have selected the most significant articles by leading academics,...

After World War II, several late-developing countries registered astonishingly high growth rates under strong state direction, making use of smart investment strategies, turnkey factories, and reverse-engineering, and taking advantage of the postwar global economic boom. Among these economic miracles were postwar Japan and, in the 1960s and 1970s, the so-called Asian Tigers—Singapore, South Korea, and Taiwan—whose experiences epitomized the analytic category of the "developmental state." In Bet...

This new volume, Nanomedicine for the Treatment of Disease: From Concept to Application, looks at the application of nanomedicines with a particular focus on their use in the treatment of diseases. The chapters in this volume, contributed by eminent scientists, researchers, and nanotechnologists from across the globe, highlight key advancements, challenges, and opportunities in the area of application of nanomedicines for disease treatment. They explore the design and development of therapeutic...

In recent years there have been dramatic changes in the pharmaceutical promotional landscape, affecting both consumers and healthcare professionals. One consequence of these dynamics is the need for pharmaceutical companies to plan new kinds of dialogue and relationships with their stakeholders. The evolution has been from mass-channel "push" marketing to two-way, multi-channel relationship marketing. Targeted Emails, webinars, mobile messages, and social networks are expanding in usage. This b...

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing—atom by atom—both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to finish, as you...